US 12,312,404 B2
Anti-PVRIG antibodies and methods of use
Mark White, Antioch, CA (US); Sandeep Kumar, San Bruno, CA (US); Christopher Chan, South San Francisco, CA (US); Spencer Liang, San Mateo, CA (US); Lance Stapleton, Oakland, CA (US); Andrew W. Drake, Mountain View, CA (US); Yosi Gozlan, Tel Aviv (IL); Ilan Vaknin, Tel Aviv (IL); Shirley Sameah-Greenwald, Kfar Saba (IL); Liat Dassa, Tel Aviv (IL); Zohar Tiran, Oranit (IL); Gad S. Cojocaru, Tel Aviv (IL); Leonard Presta, San Francisco, CA (US); and Richard Theolis, Santa Cruz, CA (US)
Assigned to Compugen Ltd., Holon (IL)
Filed by Compugen Ltd., Holon (IL)
Filed on Aug. 11, 2023, as Appl. No. 18/448,870.
Application 15/277,980 is a division of application No. 15/048,967, filed on Feb. 19, 2016, granted, now 10,227,408, issued on Mar. 12, 2019.
Application 18/448,870 is a continuation of application No. 16/904,510, filed on Jun. 17, 2020, granted, now 11,795,220.
Application 16/904,510 is a continuation of application No. 16/748,695, filed on Jan. 21, 2020, granted, now 11,623,955, issued on Apr. 11, 2023.
Application 16/748,695 is a continuation of application No. 15/277,980, filed on Sep. 27, 2016, granted, now 11,220,542, issued on Jan. 11, 2022.
Claims priority of provisional application 62/235,823, filed on Oct. 1, 2015.
Claims priority of provisional application 62/141,120, filed on Mar. 31, 2015.
Claims priority of provisional application 62/118,208, filed on Feb. 19, 2015.
Prior Publication US 2024/0101669 A1, Mar. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 7/06 (2006.01); C12N 15/113 (2010.01); G01N 33/574 (2006.01)
CPC C07K 16/2803 (2013.01) [C07K 7/06 (2013.01); G01N 33/57484 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/70 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01); C12N 15/1138 (2013.01); C12N 2310/14 (2013.01); G01N 2333/47 (2013.01)] 16 Claims
 
1. A composition comprising an anti-PVRIG antibody, wherein the anti-PVRIG antibody specifically binds to human PVRIG, wherein the antibody comprises a heavy chain and a light chain, and wherein:
a) the heavy chain comprises a heavy chain variable domain having at least 90% or at least 95% identity to the amino acid sequence of SEQ ID NO: 1434; and
b) the light chain comprises a light chain variable domain having at least 90% or at least 95% identity to the amino acid sequence of SEQ ID NO:1453.